key: cord-0955053-3xjopkv0
authors: Galassi, Giuliana; Marchioni, Alessandro
title: Acute neuromuscular syndromes with respiratory failure during COVID-19 pandemic: where we stand and challenges ahead
date: 2022-04-29
journal: J Clin Neurosci
DOI: 10.1016/j.jocn.2022.03.048
sha: 9f4742c6b049a2a7a2db5b2f5e1c897d1e53eea4
doc_id: 955053
cord_uid: 3xjopkv0

Coronavirus disease 2019 (COVID-19), a disease caused by the novel betacoronavirus SARS-COV-2, has become a global pandemic threat. SARS- COV-2 is structurally similar to SARS-COV, and both bind to the angiotensin-converting enzyme 2 (ACE2) receptor to enter human cells. While patients typically present with fever, shortness of breath, sore throat, and cough, in some cases neurologic manifestations occur due to both direct and indirect involvement of the nervous system. Case reports include anosmia, ageusia, central respiratory failure, stroke, acute necrotizing hemorrhagic encephalopathy, toxic-metabolic encephalopathy, headache, myalgia, myelitis, ataxia, and various neuropsychiatric manifestations. Some patients with COVID-19 may present with concurrent acute neuromuscular syndromes such as myasthenic crisis (MC), Guillain–Barré syndrome (GBS) and idiopathic inflammatory myopathies (IIM); these conditions coupled with respiratory failure could trigger a life-threatening condition. Here, we review the current state of knowledge on acute neuromuscular syndromes with respiratory failure related to COVID-19 infection in an attempt to clarify and to manage the muscle dysfunction overlapping SARS-COV-2 infection.

(SARS-COV-2) [1] [2] [3] . Although the large majority of patients infected with SARS-COV-2 have mild symptoms, a proportion of cases develop acute respiratory distress syndrome (ARDS ) and multiorgan failure [1] [2] [3] .

Previous works [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] highlighted neurologic manifestations in patients infected with the coronaviruses.The infection potentially arises from hematogenous spread and/or neuronal retrograde dissemination. Similar to other coronaviruses, SARS-COV-2 binds to the angiotensin-converting enzyme 2 (ACE2) receptor to access human cells [1] [2] [3] [4] [5] [6] . Since intranasal infection of mice with either SARS or MERS results in virus access to the brain, it is likely that SARS-COV-2 can also penetrate the nervous system [1] [2] [3] [4] [5] [6] .Entry to the central nervous system (CNS) would be facilitated by the expression of the SARS-COV-2 receptor ACE2 in the brain, where it acts as a cell surface peptidase present on the surface of endothelial cells, arterial smooth muscle cells and neurons [6, [9] [10] [11] . Management of neuromuscular diseases (NMD) becomes a challenge since most of them are chronic, disabling, progressive and may require immunosuppressive drugs. The respiratory failure related to COVID-19 in patients with acute NMD can arise from distinct conditions: 1) the immune-mediated viral damage of the lung, 2) the dysfunction of the respiratory muscles [1] [2] [3] [4] [5] [6] 9, 10] . From a pathogenetic point of view, the cytokine storm (CSS) and the immunological dysregulation constitute the underlying mechanism common to these two conditions.The aim of this review is to summarize the current knowledge on the pathogenesis and management of acute NMD with respiratory failure during COVID-19 pandemic .

The CSS associated with a dysregulated immune response represents a main pathogenetic mechanism of severe COVID-19 disease, which encompasses fever, coughing, dyspnea and pneumonia [9, 11, 13, 14] .In most severe cases, cytokine release shows clinical and laboratory features similar to hemophagocytic lymphohistiocytosis or macrophage activation syndrome (HLH/MAS), a hyperinflammatory disease characterized by hyper-cytokinaemia and multiorgan failure [13, 14] .

HLH/MAS typically exhibits high fever, elevated ferritin levels and hypertriglyceridemia associated with massive release of different cytokines. Interleukin 6 release (IL-6) and the activation of endothelial cells are both hallmarks of HLH/MAS, but also of severe SARS-COV-2 infection, and play an important role in vascular leakage, activation of the complement and coagulation cascade [14] .The hyperinflammatory status related to severe COVID-19 is characterized by upregulation of proinflammatory cytokines such as IL-1 IL-6, IL-7, IL-17, TNF-, granulocyte-colony stimulating factor (g-CSF), interferon- inducible protein 10, monocyte chemoattractant protein 1, and macrophage inflammatory protein 1-, thus resembling the cytokine profile described in HLH/MAS [ 15] .Moreover, a subset of patients who died from severe SARS-CoV-2 infection showed hemophagocytosis in the pulmonary lymph nodes, a typical marker of HLH/MAS [16, 17] . However, while in HLH/MAS, the immunological derangement is accompanied by systemic disseminated intravascular coagulation and hepatosplenomegaly, in severe COVID-19,the pathological manifestations are observed mainly in the lung, with development of ARDS and pulmonary thrombotic microangiopathy [16, 17] .Furthermore, ferritin, a marker of disease activity and macrophage activation typically hyper-expressed in HLH/MAS, is upregulated in response to IL-1 and IL-6 during severe SARS-COV-2 infection and showed a correlation with poor outcome, suggesting a further amplification of the inflammatory process [16, 17] .The magnitude of CSS in SARS-COV-2 infection may be enhanced by the immunological dysregulation described in patients with severe COVID-19 [13] [14] [15] . Regulatory T cells (Tregs) are a subset of CD4 T cells which have a   role in inducing immune tolerance, preventing autoimmune diseases and limiting aggressive immune responses to viral infections [18] . Decrease of Treg levels in peripheral blood could play a role in the inability to limit cytokine storm and in delaying the resolution of acute lung injury [18, 19] .Treg depletion has been described in severe COVID-19, but also in other viral infections such as respiratory syncytial virus (RSV) [19] . Imbalance between regulatory (i.e. Tregs) and effector arms (i.e. neutrophils, Th17 cells, macrophages, dendritic cells) of immune response, ultimately results in virus-induced inflammatory tissue damage inducing ARDS development but also affecting other organs, including the nervous system [20] .Indeed, in a murine-model of acute encephalitis induced by coronavirus, Treg depletion is associated with amplification of tissue damage and poor outcome [21] .Moreover,Treg depletion in animal model of RSV infection increased inflammatory cytokine and chemokine release in the airway and enhanced cellular influx into the lungs promoting tissue injury [22] .

Patients affected by COVID-19 exhibit flu-like symptoms (i.e. fever, fatigue, myalgias, cough) in 81% of cases, while in about 14% of cases severe disease usually occur 1 week after the onset of symptoms with hypoxemia and progressive development of acute respiratory failure [1] [2] [3] [5] [6] [7] [8] [9] 12] .

Among the hospitalized patients, up to 30% require ICU care , with mortality rates ranging between 20% and 26% in the critically ill, but this rate can reach 88% in patients undergoing mechanical ventilation (MV) [5] . The time course of SARS-COV-2 manifestations in patients with more severe disease appears to be related to low innate antiviral defenses and high pro-inflammatory cues of cytokine storm development [1, 3, 5, 9, [13] [14] [15] [16] [17] 23] . SARS-COV-2 elicits an initial weak IFN response followed by IFN peak levels resulting in a delayed neutrophil recruitment in the lungs, a prolonged immune stimulation and an increased peak of cytokine, with development of lung injury 7-10 days after the onset of symptoms [24] [25] [26] .

From a pathogenesis standpoint, SARS-COV-2 infects alveolar cells replicating in lung tissue and inducing recruitment of leukocytes related to the upregulation of chemokine profile. Transcriptional analysis of bronchiolar-lavage fluid obtained from patients affected by COVID-19 showed overexpression of CXCL-2 and CXCL-8 chemokines, that play a critical role in the recruitment of polymorphonuclear cells into the lung [27] . Activated neutrophils accumulation in the alveolar spaces induces reactive oxygen species (ROS) release, such as superoxide radicals and H2O2 and proteolytic enzyme secretion (i.e. neutrophil elastase), leading to damage in the alveolar-capillary barrier, inflammatory edema formation and activation of coagulation [27, 28] . Furthermore, the release of neutrophils extracellular traps (NETs) in an attempt to contain the viral infection may play a role in enhancing lung injury and microvascular thrombosis in COVID-19 [28, 29] . NETs consist of extracellular DNA fibers comprised of histone and cytoplasmic granule proteins, that provide a scaffold for the binding of platelets, red blood cells and plasma proteins. NETs could act with the immobilization of viruses and bacteria and with the reduction of inflammation through cytokines and chemokines degradation [30] . On the other hand, NETs are also implicated in enhanced tissue injury via endothelial damage and microvascular thrombosis [31] .

In COVID-19 pneumonia, the impaired lung perfusion due to pulmonary angiopathy and thrombosis plays a major role in the pathogenesis of respiratory failure, especially in patients with non-ARDS radiological findings [32] . Furthermore, the pathological perfusion in COVID-19 lungs includes disruption of the renin-angiotensin system (RAS) and severe endothelial injury with loss of hypoxic pulmonary vasoconstriction function [32] . SARS-COV-2 binding to receptors results in downregulation and loss of ACE2 function in lung, producing dysregulation of the RAS system . Indeed, ACE2 acts through negative regulation of the RAS system by converting angiotensin II to angiotensin 1-7, which stimulates the vasodilatation of lung vasculature via nitric oxide release, and exerts anti-inflammatory activity [32] . Thus, the download of ACE receptors caused by the virus leads to an increased synthesis of angiotensin II in the lung that may result in an alteration of hypoxic pulmonary vasoconstriction with worsening of ventilation-perfusion mismatch ( Figure 1 ). Finally, the respiratory failure is the result of severe viral alveolitis and concomitant pulmonary perfusion dysfunction, which justifies the heterogeneity of the clinical presentations with different radiological patterns ( Figure 1 ). The marker of respiratory failure due to lung and perfusion injury is hypoxemia without hypercapnia.

Peripheral (PNS ) and CNS diseases related to SARS-COV-2 infection may arise from different pathways of virus-mediated tissue injury: 1) hematogenous or trans-neuronal route, 2) CSS and blood brain barrier (BBB) damage, 3) autoimmune response [1] [2] [3] [4] [5] [6] [9] [10] 15 ]. The first mechanism seems related to the most common neurological symptoms of SARS-COV-2 infection such as hypogeusia, hyposmia, headache, vertigo, and dizziness. It has been speculated that SARS-COV-2 infected damaged endothelial cells of the BBB allow direct passage into the CNS [1] [2] [3] [4] [5] [6] [9] [10] 15] . As a second major route of entry to the CNS, the axonal transport machinery represents a potential route of entry to the CNS via the cranial nerves .Indeed ,the olfactory nerve serves as a shortcut for many viruses through olfactory receptor neurons projecting dendrites into the nasal cavity and extending axons across the cribriform plate into the olfactory bulb [4, 11] . Furthermore, CSS could result in the breakdown of the BBB without direct viral invasion, causing the development of acute coagulopathy which could render patients prone to cerebrovascular events, both thrombotic and hemorrhagic [9, [13] [14] [15] [16] [17] . Although there is no evidence that patients with NMD exhibit a higher infection risk of COVID-19, NMD and its associated therapies may affect the patient's ability to cope with infection or its systemic effects. Indeed the onset and / or the exacerbation of PNS disorders during SARS-COV-2 infection could be related to a variety of mechanisms, which might include the activation of autoimmune response with molecular mimicry mechanism, bystander activation and epitope spreading [33, 34] .Previous reports has shown that different tissue antigens share sequence homology with the virus suggesting antibody cross-reactivity as an underlying mechanism of autoimmune neurological diseases [33] . Lucchese and Flöel [33] recently reported three human proteins (namely DAB1, AIFM, and SURF1, as catalogued at www.uniprot.org) that are present in neurons of the respiratory pacemaker in the brainstem, potentially sharing antigenic epitopes with SARS-COV-2.

Particularly, these authors [33] postulated that damage to the brainstem pacemaker may contribute to respiratory failure in COVID-19 as a consequence of molecular mimicry between neuronal and viral proteins, in turn causing the clinical dissociation between well-preserved lung mechanics and severity of hypoxemia. Sequence analysis of the 41 human proteins associated with acute and chronic immune-mediate neuropathies pointed out that SARS-CoV-2 shares two hexapeptides (KDKKKK and EIPKEE) with the human heat shock proteins 90 and 60 , which however are not specific for NMD, but can be found in other autoimmune disorders [33] .These studies however may support the view of a potential immune-mediated mechanism in the onset of PNS diseases during SARS-COV-2 infection, although it cannot be excluded that the massive release of cytokines and Tregs/Th-17 imbalance could contribute to the pathogenesis of these diseases ( Figure 2 ) . Indeed, Tregs depletion in severe COVID-19 plaies a role in promoting autoimmune disorder through a defect in selftolerance and abnormal immune-response to self-antigens [34] [35] [36] .

Several reports show that SARS-CoV2 infection can promote the onset of acute hypercapnic respiratory failure ("pump failure") due to respiratory muscles weakness, both by triggering the onset of acute NMD through an autoimmune mechanism or eventually by an acute exacerbation of a preexisting condition, such as myasthenia gravis (MG) or myotonic dystrophy(DM1) [34, [37] [38] [39] [40] [41] [42] .

Acute respiratory failure in NMD is the result of weakness of different muscle groups, which have distinct effects on respiratory function.The weakness of muscles of the upper airway (facial, oropharyngeal and laryngeal muscles) induces dysphagia, risk of aspiration and upper airway occlusion [43] , whereas the inspiratory muscle dysfunction causes hypoventilation and CO 2 retention, mainly involving the diaphragm, although intercostals and accessory muscles weakness may be affected. When the weakness of inspiratory muscles is excessive, the ventilatory pump is unable to sustain the load necessary for ventilation and the appearance of microatelectasis leads to hypoxemia and reduction of lung compliance, resulting in further increase of elastic load [44] . Clinically, the patient exhibits "rapid shallow breathing" , characterized by high respiratory rate and low tidal volumes (V T ), preceding the onset of hypercapnic respiratory failure. Finally, expiratory muscles weakness causes ineffective cough and the inability to clear bronchial secretions, predisposing the patient to pneumonia and airways obstruction. Figure 2 summarizes the pathophysiology of respiratory failure in NMD during the course of COVID-19.

Clinical features of patients with MG and respiratory failure described in the English literature are listed in Table 1 [38] [39] [40] 42, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] . MG may be a risk factor for severe COVID-19 disease for many reasons, including an immunocompromised state related to baseline therapies, respiratory muscle weakness or disease exacerbation after immunotherapy cessation [38, 39] . We previously discussed the imbalance between inflammatory T-helper 17 (Th-17) cells and Treg cells in severe COVID-19 disease, which could also play a role in MG expression [34] . Restivo et al [47] reported 3 patients without a pre-existing diagnosis of MG who developed acute ocular and bulbar signs overlapping a concurrent SARS -COV-2 infection; in these cases however a pre-existing disorder of the neuromuscular junction exacerbated by the SARS-COV-2 pneumonia could not be excluded as the neurological symptoms started within 5 to 7 days after the fever onset with a parainfectious more than a post-infectious profile. Camelo-Filho et al [39] published the largest series of cases, noting that most patients had severe course as 87% were admitted in ICU, 73% needed MV and 30% died. On the contrary in a series of 93 Czech patients, only 34 were were hospitalized and none exhibited a myasthenic crisis (MC) [57] . Businaro et al [51] recently published a report on 162 Italian patients interviewed during the first wave of the pandemic: only 11 had probable/confirmed infection and of those, only 3 required ventilator support: 2 elderly died of respiratory insufficiency whereas only 1 experienced worsening MG symptoms.These authors [51] concluded that risk of COVID-19 in MG patients seems to be no higher than that of the general population, regardless of immunosuppressive therapies. Rodrigues et al [58] reported a case series of patients with MG exacerbation or crisis associated with COVID-19 and described an in-hospital mortality rate of 25% and a higher rate (37.5%) at 2-month follow-up, concluding that mortality of MC due to COVID-19 is higher than those due to other etiologies.

Several GBS cases with respiratory failure during COVID-19 pandemic are described in the English literature at the time of this writing . Toscano et al first [59] reported 5 patients, 4 with clinical diagnosis of GBS and 1 of facial diplegia and paraesthesia variant: 3 needed MV in absence of dysautonomia. Toscano et al [59] rose an important point as whether the reduced vital capacity in these cases was proportional to muscular weakness and to the extent of the chest abnormalities. Abu-Rumeileh et al [37] reviewed data from 73 cases of GBS and found that in analogy to the classic GBS approximately one-fifth of COVID-19-associated GBS required MV during hospitalization. Uncini et al [61] described respiratory failure in about one-third of patients and ICU admission in at least 40% of patients. Filosto et al [62] during the outbreak in northern Italy, reported a statistically significant high rate of ICU admission, as compared to GBS without SARS-COV-2 infection, whereas Keddi et al [63] in a cohort study in the UK did not support significant causal link between COVID-19 infection and GBS. In the series published by Sriwastava et al [64] who reviewed 50 cases obtained from 37 studies , 30% of patients presented poor outcomes secondary to respiratory failure and 60% required MV. Sriwastava et al [64] suggested that COVID-19 is a trigger for a rapidly progressing neuropathy although some of the need for ventilator support might be related to lung damage from the infection itself.

Myopathy with elevated blood-creatine kinase (CK) levels are described in patients with SARS-COV-2 infection and myalgias are common manifestations ,while serum CK elevation might depend on clinical severity, ranging from mild to frank rhabdomyolysis [ 1, 2, 9, . Gupta et al [94] stated that the dermatomyositis is the most frequent subtype (40%) of inflammatory myopathies, attributable to COVID-19 pandemic; Mehan et al [95] described 7 patients with paraspinal myositis and 4 were intubated over their hospital stay. Rosato et al [96] reviewed 16 case reports from existing literature and discussed the COVID-19 -related rhabdomyolysis in one patient who developed acute muscle weakness, renal failure, hypoxia. Table 3 shows adult cases of acute myopathies with respiratory failure with or without rhabdomyolysis during COVID-19 pandemic.

Dhont et al [41] described 3 patients with DM1 and SARS-COV-2 infection. receiving non-invasive nocturnal home ventilatory support. Despite maximal supportive care, all 3 died. Dhont et al [41] observed that the mutant RNA-transcript with expanded CUG repeats could act as a trigger for critical elevation of TNF-α, IL-6, and IL-1β cytokines already described in DM1. Quinlivan et al 

SARS-COV-2 infection in patients with pre-existing NMD could cause an unpredictable deterioration of the respiratory conditions, leading to acute respiratory "pump failure" due to respiratory muscle weakness with CO2 retention (Figure 2 ). The respiratory muscle monitoring has a key role in the decision-making process of the respiratory management in spontaneous breathing of patients with NMD. A reliable non-invasive respiratory muscle assessment, either in a regular word or in ICU is challenging.The non-invasive surrogate markers for diaphragm weakness include maximum static inspiratory mouth pressure (PI max ), maximal sniff nasal inspiratory pressure (SNIP), and vital capacity (VC), which are the most useful measures of respiratory muscle functions used bedside in the hospital setting. PI max is obtained with a maximal inhalation against a closed valve, and reflects the strengths of diaphragm, but also the external intercostal and accessory muscles.While normal values form PI max vary by age and gender, there is agreement in considering a PI max value < 30 cmH2O suggestive of severe respiratory muscles weakness. SNIP is recorded by pressure transducer connected to a catheter placed in the nostril during a quickly and deeply sniffing maneuver, which determines nasal valve collapses [116, 117] The sniff maneuver is easier to perform than the PI max in patients with bulbar involvement with weak lips, and provides a reliable estimation of sniff esophageal and transdiaphragmatic pressure in patients with NMD . A SNIP < 40 cmH2O, associated to symptoms or signs related to respiratory weakness, was proposed by EFNS Task force to initiate NIV in patients with ALS [118] . However, validated data about SNIP in acute NMD requiring ICU care are not available.

VC is the volume obtained with a full exhalation after maximum inspiration up to total lung capacity (TLC). VC less than 50% of predicted is associated with several bilateral diaphragm weaknesses, but this value can further decrease to 30% or more when patient is supine [117] .In the last few years, diaphragmatic assessment with ultrasound (US) has proven to be a quick and easy technique for evaluating of diaphragm function, because it requires minimal cooperation from the patient. In this scenario, variations in diaphragm thickness in the apposition zone (ZOA) may suggest paralysis or severe dysfunction. Findings consistent with severe muscle dysfunction or paralysis are : absence of diaphragm excursion , presence of paradoxical motion (diaphragm move cephalad during inspiration) thickening fraction( TF < 20%) [119] . Bedside diaphragm US is useful to rule out or to confirm severe diaphragm dysfunction particularly in NMD that can present acute respiratory failure due to rapid inability of diaphragm pump, such as MG and GBS.

Most studies conducted during the COVID-19 outbreak reported that 10-20% of the hospitalized patients undergo some form of ventilatory support, either in the ward or in ICU [120] .The decision whether or not to intubate patients with severe disease is an essential component of the patient care.

Excessive work of breathing, severe refractory hypoxemia, alteration of consciousness or coma, all are factors that must be considered for the indication for tracheal intubation and MV [23] . However, in most cases, a trial with a non-invasive respiratory support (NIV) is indicated before deciding on the need for intubation. The most commonly respiratory support used include high-flow nasal oxygen (HFNO) and NIV through face mask interfaces or helmet, although it is not yet known which respiratory support is preferable in COVID-19 respiratory failure. Grieco et al [121] reported the results of a multicenter randomized clinical trial comparing helmet NIV vs HFNO in moderate to severe respiratory failure related to COVID-19.Although no difference was noted regarding the primary outcome (days free of respiratory support within 28 days), treatment with helmet NIV was associated with improved oxygenation and reduced rate of endotracheal intubation [121] .

Furthermore, in severe COVID-19 patients with hypoxic lung damage requiring any type of respiratory support (oxygen, HFNO, NIV), immunomodulatory treatment either steroids or others, might enhance improvements in the clinical outcomes. The RECOVERY trial, a large randomized controlled trial, has shown that the use of dexamethasone in hospitalized COVID-19 patients who received either invasive MV or oxygen alone, resulted in lower 28-day mortality, while no benefit was found among patients who did not require oxygen [122] . Furthermore, Tocilizumab, a recombinant humanized anti-IL-6 receptor monoclonal antibody, in a large randomized trial showed additional survival benefit in patients already treated with corticosteroids, and the improvement of other clinical outcomes such as reduced chances of requiring invasive MV and increased chances of successful hospital discharge [123] .

In patients with NMD during SARS-COV-2 infection, the timing of elective intubation is crucial; it can be decided on the previously mentioned criteria, but also on functional assessment of the respiratory muscles which are the following : VC less than 20 ml/Kg, PI max less than 30 cmH 2 O and maximal expiratory pressure (MEP) less than 40 cmH 2 O or a reduction of more than 30% in any of these measures which are the suggested thresholds as a guide for elective endotracheal intubation in patients with NMD [124] .

Nowadays ,there is no evidence from randomized trials to support the routine use of NIV instead of MV in patients with acute respiratory failure in NMD. However, data obtained from observational studies suggests that a trial of NIV can be attempted, except for cases exhibiting bulbar dysfunction and excessive bronchial secretions [125] . Indeed in GBS, the use of NIV is debated and might be ineffective in presence of bulbar dysfunction and because of the length of time necessary for respiratory muscles to recover [63] . Indeed, in patients with MC demanding ventilation, NIV reduced the need for invasive ventilation up to 38% of cases [126] and it was associated with shorter duration of ventilation, ICU stay and reduction of pulmonary complications, such as atelectasis and pneumonia. In our experience, an early NIV treatment in patient outside ICU setting showed a further reduction of the need for MV in MC patients [127] . NIV could be the first approach in selected patients, but this choice depends on the severity of the respiratory muscle involvement and on the underlying disorders. The outcomes of MG and GBS requiring MV were studied by Vellipuram et al [128] , who found that GBS patients had higher in-hospital complications and disability at discharge compared with MG subjects.

Respiratory failure during SARS-COV-2 infection is a complex phenomenon. In the most severe form of COVID-19, the variable association between viral alveolitis and impaired pulmonary perfusion constitutes the main mechanism underlying the onset of hypoxemia. However, the immunological response triggered by virus-host interactions may promote the acute development of muscular weakness, or it can exacerbate an already existing condition. Non-invasive monitoring of respiratory muscles is challenging and indeed it could be essential to diagnose the onset of respiratory dysfunction in patients with suspected or pre-existing NMD overlapping SARS-COV-2 infection .

Successful management of NMD with respiratory failure during COVID-19 pandemic is dependent upon a high clinical index of suspicion and early diagnosis. Onset of Guillain-Barré Syndrome or Myasthenia Gravis may precipitate weakness of respiratory muscles. that can ultimately lead to acute hypoventilation and Co2 retention.

Credit authorship contribution statement GG: Conceptualization, methodology, writing -review and editing.AM: Conceptualization, methodology, writing -review and editing. 

 Respiratory failure in the course of SARS-COV-2 infection is a complex phenomenon whose pathophysiology has not yet been fully understood.

 In the more severe form of COVID-19, the variable association between viral alveolitis and impaired pulmonary perfusion constitutes the main mechanism underlying the onset of hypoxemia in most cases.

 The immunological derangement triggered by virus-host interactions may promote the development of acute neuromuscular diseases, or it can exacerbate an already existing neuromuscular condition , causing weakness of respiratory muscles and alveolar hypoventilation.

 Non-invasive monitoring of respiratory muscles may be very challenging, but could be essential to diagnose the onset of respiratory muscle dysfunction in patients with suspected or pre-existing neuromuscular disorders.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical and immunological features of severe and moderate coronavirus disease 2019

First Case of 2019 Novel Coronavirus in the United States

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Clinical and Autoimmune Characteristics of Severe and Critical Cases with COVID-19

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Neurological Complications during Treatment of Middle East Respiratory Syndrome

Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Simani L Central nervous system manifestations of COVID-19: A systematic review

Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

Acute respiratory distress syndrome: the berlin Definition

Cytokine release syndrome

The looming storm: Blood and cytokines in COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Cytokine Storm in Coronavirus Disease 2019 and Adult-Onset Still's Disease: Similarities and Differences

Toward an understanding of regulatory T cells in COVID-19: A systematic review

Depletion of circulating regulatory T cells during severe respiratory syncytial virus infection in young children

Th17 and regulatory T cell balance in autoimmune and inflammatory diseases

Role of regulatory T cells in coronavirusinduced acute encephalitis

Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection

Severe Covid-19

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm

Autoantibodies against type I IFNs in patients with lifethreatening COVID-19

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

Neutrophils and COVID-19: The road so far

et Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Neutrophil extracellular traps: double-edged swords of innate immunity

The role of neutrophils and NETosis in autoimmune and renal diseases

Pulmonary Angiopathy in Severe COVID-19: Physiologic, Imaging, and Hematologic Observations

SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism

Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay

Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome

The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease

Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases

COVID-19 in patients with myasthenia gravis. Muscle Nerve

COVID-19 Presentation in Association with Myasthenia Gravis: A Case Report and Review of the Literature

Myotonic dystrophy type 1 as a major risk factor for severe COVID-19?

Management of patients with generalised myasthenia gravis and COVID-19: four case reports

Practical approach to respiratory emergencies in neurological diseases

Neuromuscular disease causing acute respiratory failure

Myasthenia gravis and COVID-19: A case series and comparison with literature

Myasthenic crisis in COVID-19

Gravis Associated With SARS-CoV-2 Infection

Case series: COVID-19 in patients with mild to moderate myasthenia gravis in a National Referral Hospital in Indonesia. eNeurologicalSci

Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up

Description of 3 patients with myasthenia gravis and COVID-19

COVID-19 in patients with myasthenia gravis: Epidemiology and disease course. Muscle Nerve

Case series of COVID-19 in patients with myasthenia gravis: a single institution experience

COVID-19 and generalized Myasthenia Gravis exacerbation: A case report

Myasthenic crisis in the setting of Coronavirus Disease 2019 (COVID-19)

Respiratory dysfunction as first presentation of myasthenia gravis misdiagnosed as COVID-19

Isolated COVID-19 Infection Precipitates Myasthenia Gravis Crisis: A Case Report

Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival

Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review

Guillain-Barré Syndrome Associated with SARS-CoV-2

Guillain-Barré Syndrome associated with SARS-CoV-2 infection

Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic

Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions

Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome

Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series

Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: A systematic review and meta-analysis

Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication

A Case of Guillain-Barré Syndrome Associated With COVID-19

Acute polyradiculoneuritis with lockedin syndrome in a patient with Covid-19

Guillain-Barré syndrome following COVID-19: new infection, old complication?

SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with a favourable outcome

Guillain-Barré syndrome related to COVID-19 infection

New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases

Guillain-Barré Syndrome with Facial Diplegia Related to SARS-CoV-2 Infection

Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain-Barré syndrome and polyneuritis cranialis in COVID-19 patients: A case series

Guillain-Barré syndrome in a patient with antibodies against SARS-COV-2

SARS-CoV-2-associated Guillain-Barré syndrome with dysautonomia

Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital

Guillain-Barre Syndrome and COVID-19: A case report

Fatal Guillain-Barre syndrome after infection with SARS-CoV-2

Acute inflammatory demyelinating polyneuropathy or Guillain-Barré syndrome associated with COVID-19: a case report

Guillain-Barré syndrome after Covid-19 infection

Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease

Guillain-Barré syndrome in the COVID-19 era: another occasional cluster?

SARS-CoV-2 associated Guillain-Barré syndrome

Novel Coronavirus (COVID-19)-Associated Guillain-Barré Syndrome: Case Report

Guillain-Barré-Strohl syndrome and COVID-19: Case report and literature review

COVID-19 may induce Guillain-Barré syndrome

Case Report: Guillain-Barré Syndrome Associated With COVID-19

Concomitant Guillain-Barre syndrome with COVID-19: a case report

Guillain-Barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: A case series

Covid-19 associated Guillain-Barre Syndrome: Contrasting tale of four patients from a tertiary care centre in India

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

COVID-19 and myositis -unique challenges for patients

Acute myopathic quadriplegia in patients with COVID-19 in the intensive care unit

Clinical, electromyographical, histopathological characteristics of COVID-19 related rhabdomyolysis

COVID-19-associated myositis with severe proximal and bulbar weakness

Adolescent COVID-19-Associated Fatal Rhabdomyolysis

A Rare Presentation of Coronavirus Disease 2019 (COVID-19) Induced Viral Myositis With Subsequent Rhabdomyolysis

Rhabdomyolysis as Potential Late Complication Associated with COVID-19

Rhabdomyolysis as a Presentation of

Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19

Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis

Patient Presenting with Mild Rhabdomyolysis

Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature

Rhabdomyolysis in COVID-19: Report of Four Cases

Rhabdomyolysis and acute kidney injury in severe COVID-19 infection

Case report of COVID-19 in an elderly patient: could SARS-CoV2 trigger myositis?

Acute myopathic quadriplegia in patients with COVID-19 in the intensive care unit

Rhabdomyolysis as a manifestation of a severe case of COVID-19: A case report

COVID-19 or clinical amyopathic dermatomyositis associated rapidly progressive interstitial lung disease? A case report

Myositis due to COVID-19

COVID-19 and Myositis: What We Know So Far

Clinical outcome of SARS-CoV-2 infection in 7 adults with Duchenne muscular dystrophy attending a specialist neuromuscular centre

Accelerated Early Progression of Amyotrophic Lateral Sclerosis over the COVID-19 Pandemic

ATS/ERS Statement on respiratory muscle testing

ERS statement on respiratory muscle testing at rest and during exercise

EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force

Serial ultrasound assessment of diaphragmatic function and clinical outcome in patients with amyotrophic lateral sclerosis

Mechanical ventilation parameters in critically ill COVID-19 patients: a scoping review

Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial

Dexamethasone in Hospitalized tPatients with Covid-19

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Acute Manifestations of Neuromuscular Disease

Invasive versus non-invasive ventilation for acute respiratory failure in neuromuscular disease and chest wall disorders. Cochrane Database Syst Rev

Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases

Predictors of outcome in patients with myasthenic crisis undergoing non-invasive mechanical ventilation: A retrospective 20 year longitudinal cohort study from a single Italian center

Comparative Outcomes of Respiratory Failure Associated with Common Neuromuscular Emergencies: Myasthenia Gravis versus Guillain-Barré Syndrome